| |
Total (n = 238)
|
Class 1 (n = 75)
|
Class 2 (n = 51)
|
Class 3 (n = 32)
|
Non-class 1–3 (n = 80)
|
P-value (1 vs. 2)
|
P-value (1 vs. 3)
|
P-value (2 vs. 3)
|
|---|
|
Age
|
0.87
|
0.70
|
0.75
|
|
Median (range)
|
61 (33–86)
|
61 (42–82)
|
61 (45–81)
|
62 (47–81)
|
59 (33–86)
|
|
Gender
|
0.008
|
0.017
|
1
|
|
Male
|
156 (65.5%)
|
38 (50.7%)
|
39 (76.5%)
|
25 (78.1%)
|
54 (67.5%)
|
|
Female
|
80 (33.6%)
|
35 (46.7%)
|
12 (23.5%)
|
7 (21.9%)
|
26 (32.5%)
|
|
NA
|
2 (0.8%)
|
2 (2.7%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
|
Histology
|
0.74
|
0.88
|
0.81
|
|
Adenocarcinoma
|
188 (79.0%)
|
60 (80.0%)
|
40 (78.4%)
|
28 (87.5%)
|
60 (75.0%)
|
|
Squamous cell carcinoma
|
18 (7.6%)
|
2 (2.7%)
|
3 (5.9%)
|
1 (3.1%)
|
12 (15.0%)
|
|
Adenosquamous carcinoma
|
27 (11.3%)
|
10 (13.3%)
|
7 (13.7%)
|
3 (9.4%)
|
7 (8.8%)
|
|
Large cell carcinoma
|
5 (2.1%)
|
3 (4.0%)
|
1 (2.0%)
|
0 (0%)
|
1 (1.2%)
|
|
Stage
|
1
|
1
|
1
|
|
Stage IA–IIIA
|
67 (28.2%)
|
20 (26.7%)
|
14 (27.5%)
|
9 (28.1%)
|
24 (30.0%)
|
|
Stage IIIB–IVB
|
164 (68.9%)
|
54 (72.0%)
|
35 (68.6%)
|
21 (65.6%)
|
54 (67.5%)
|
|
NA
|
7 (2.9%)
|
1 (1.3%)
|
2 (3.9%)
|
2 (6.3%)
|
2 (2.5%)
|
|
Metastasis
|
0.43
|
0.63
|
1
|
|
M0
|
171 (71.8%)
|
55 (73.3%)
|
34 (66.7%)
|
22 (68.8%)
|
60 (75.0%)
|
|
M1
|
67 (28.2%)
|
20 (26.7%)
|
17 (33.3%)
|
10 (31.2%)
|
20 (25.0%)
|
- P-values in italics-face denotes statistical significance
